Navigation Links
Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income
Date:2/26/2009

24th Consecutive Profitable Quarter Earns $.08 Per Diluted Share

LARGO, Fla., Feb. 26 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter ended December 31, 2008 (FY2009).

Net sales, excluding royalty income, increased 1.2% to $1,530,242 in FY2009 second quarter, compared with $1,512,361 in the previous year second quarter (FY2008). The increase was primarily a result of continued growth of the Company's C-Vue brand disposable specialty contact lenses, sold exclusively to licensed eye care professionals.

FY2009 second quarter net income was $358,945, compared with $375,915 in the previous year second quarter. Excluding a one-time favorable tax adjustment of $44,422 in the previous year second quarter, FY2009 second quarter net income increased 8.3%.

Royalty income for the FY2009 second quarter increased 3.0% to a record second quarter of $666,569 compared with $646,849 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to increase, resulting in continued royalty income growth.

FY2009 second quarter income before taxes increased 11.9% to a record second quarter of $606,717 compared with $542,257 in the prior-year quarter. After recording net income tax expense of $247,772, Unilens reported net income of $358,945 for the quarter, or $0.08 per diluted share. In the FY2008 second quarter, the Company reported net income of $375,915, or $0.08 per diluted share, which included income tax expense of $166,342.

"We are very pleased with our second quarter results, considering the current economic environment," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc. "Double-digit growth from our C-Vue brand of lenses sold exclusively to independent practitioners, combined with a 3% growth in royalty revenue derived from Bausch & Lomb's sales of multifocal lenses that use our key technologies, was responsible for our record performance."

"I am also pleased to report that the Unilens Board of Directors declared its regular quarterly dividend of US $0.09 per common share, payable this Friday, February 27, 2009. "This decision was based on the Company's strong balance sheet, and projected operating cash flows and is consistent with the Board's commitment that shareholders should share directly in the earnings achieved by management while continuing to execute our growth strategy," concluded Mr. Pecora.

For the six months ended December 31, 2008, net sales excluding royalty income, increased 3.3% to $3,291,768, as compared to $3,185,722 for the prior-year six months. Net sales of the Company's C-Vue brand disposable contact lenses increased approximately 11.3% during the first half of fiscal year 2009, while sales of replacement products lines declined, as expected.

Net Income for the six months increased 9.6% to $825,312, or $0.18 per diluted share, compared with $753,211, or $0.17 per diluted share in the prior-year 6 months.

Royalty income for the six months ended December 31, 2008 increased 9.6% to a record $1,379,966, compared with $1,259,648 in the prior-year 6 months, demonstrating continued demand for sales of licensed products by our licensee Bausch & Lomb.

Income before taxes for the six months ended December 31, 2008 increased 18.7% to $1,374,976, compared with $1,158,758 in the prior-year 6 months. After recording net income tax expense of $549,664, Unilens reported net income of $825,312, or $0.18 per diluted share, for the six months ended December 31, 2008. This compared with net income of $753,211, or $0.17 per diluted share, in the prior-year 6 months of fiscal year 2008, which included net income tax expense of $405,547.

About Unilens Vision Inc. - "The Independent Eye Care Professionals Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".

(Note: All financial information in this release is stated in U.S. Dollars.)

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531

                                   UNILENS VISION INC.
                               SECOND QUARTER - FISCAL 2009
                       CONDENSED CONSOLIDATED FINANCIAL INFORMATION

    (All figures in U.S.
     Dollars)
    RESULTS OF OPERATIONS
                          Three Months Three Months  Six Months   Six Months
                              Ended        Ended        Ended        Ended
                          December 31, December 31, December 31, December 31,
                              2008         2007         2008          2007


      Sales                 $1,530,242  $1,512,361  $  3,291,768   $3,185,722
      Cost of sales            873,498     885,453     1,808,630    1,789,850
                               656,744     626,908     1,483,138    1,395,872
      Expenses                 703,341     715,190     1,475,302    1,470,142
      (Loss) income from
       operations              (46,597)    (88,282)        7,836      (74,270)
      Other items:
      Royalty income           666,569     646,849     1,379,966    1,259,648
      Other expense             (9,074)    (21,775)       (6,489)     (48,916)
      Remeasurement
       (expense) income         (4,557)        471        (8,984)       3,012
      Interest income              376       4,994         2,647       19,284
                               653,314     630,539     1,367,140    1,233,028
      Income before income
       tax expense             606,717     542,257     1,374,976    1,158,758
      Income tax expense       247,772     166,342       549,664      405,547
      Net income for the
       period                 $358,945    $375,915      $825,312     $753,211
      Net income per common
       share:
        Basic                    $0.08       $0.08         $0.18        $0.17
        Diluted                  $0.08       $0.08         $0.18        $0.17
    CASH FLOWS
       Provided (used) by:
       Operating activities   $588,372    $265,988    $1,295,055     $955,246
        Investing activities   (32,461)     (1,636)      (65,061)     (29,759)
        Financing activities  (409,564)   (409,564)   (2,184,343)  (2,153,572)
       Decrease in cash       $146,347   $(145,212)    $(954,349) $(1,228,085)

    BALANCE SHEET
                               June 30,   December 31, December 31,
                                 2008         2008         2007
      Cash                   $1,603,476     $640,143     $736,639
      Total assets            6,784,128    5,272,295    6,331,743
      Current liabilities       957,434      804,632      563,301
      Total liabilities         957,434      804,632      563,301
      Stockholders' equity   $5,826,694   $4,467,663   $5,768,442


'/>"/>
SOURCE Unilens Vision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
2. Unilens Vision Acquires Aero Contact Lens, Inc.
3. Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income
4. Unilens Launches New C-VUE(R) Advanced(TM) Custom Toric Lens
5. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
6. Unilens Vision Announces New Policies Aimed at Increasing Eye Care Professionals Profitability
7. Unilens Vision Reports Increased Royalty Income
8. Unilens Launches Aspheric C-VUE(R) Daily Disposable Lens
9. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
10. Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
11. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... A book about the self-discovery of one’s limitless creative power, “ Unleash Your ... give readers the courage they need to embrace their creativity and unleash it as ... my life to learn and create what I set my heart with no limits ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... "ProDrop 3D ... projects to the next level," said Christina Austin - CEO of Pixel Film Studios. ... Studios. With ProDrop 3D Abstract have the ability to generate and manipulate three-dimensional shapes ...
(Date:5/31/2016)... ... ... According to recent statistics, there are nearly half a million physical therapists ... physical therapy professional and every clinic has a duty to perform at the highest ... competitive industry is also essential. The solution that many physical therapy leaders turn to ...
(Date:5/31/2016)... (PRWEB) , ... June 01, 2016 , ... ... “ Psoriasis and smoking: links and risks ”. , As corresponding author Professor ... on the relation between smoking habits and psoriasis. Smoking influences the onset and ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... that considers individuals’ genetic characteristics and the physical and behavioral worlds in ... in sync. In personalized medicine, diagnosing an individual’s disease depends on accurately ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... market growth is the emergence of new treatments. Cardax, ... therapies for osteoarthritis treatment. The therapy is expected to ... Arthritis Research UK is conducting studies to develop new ... study, where the genes involved in osteoarthritis are being ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
Breaking Medicine Technology: